



## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 89562

**Title:** Immunotherapy of gastric cancer: Present status and future perspectives

**Provenance and peer review:** Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05469117

**Position:** Editorial Board

**Academic degree:** PhD

**Professional title:** Adjunct Professor, Chief Physician, Deputy Director

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** Greece

**Manuscript submission date:** 2023-11-05

**Reviewer chosen by:** Yu-Lu Chen

**Reviewer accepted review:** 2023-11-11 03:50

**Reviewer performed review:** 2023-11-12 16:26

**Review time:** 1 Day and 12 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Novelty of this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
<b>Creativity or innovation of this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation



<b>Scientific significance of the conclusion in this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

**SPECIFIC COMMENTS TO AUTHORS**

Thank you for inviting me to evaluate the editorial titled “ Immunotherapy of Gastric cancer: Present status and future perspectives”.In this editorial, they briefly described the recent data concerning the epidemiological parameters of gastric cancer (GC) in different countries, attempting to give an interpretation based on the etiological factors involved in the etiopathogenesis of the neoplasm.Then they briefly discussed the conservative treatment (chemotherapy) of the various forms of this malignant neoplasm. Special attention was given to modern therapeutic approaches with emphasis on immunotherapy which seems to be the future of GC treatment, especially in combination with chemotherapy.Then they commented on the article by Li YN et al. entitled "Advances and key focus areas in gastric cancer immunotherapy: A comprehensive scientometric and clinical trial review (1999-2023)" published in the recent issue of the World Journal of Gastroenterology. Finally, they believed the trends in clinical trials were the discovery of new biomarkers and the investigation of more specific treatment options , and the combination of several therapeutic agents will constitute future therapeutic strategies.The paper is well arranged and the logic is clear, and. The cited



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** office@baishideng.com  
**https://**www.wjgnet.com

literature is comprehensive and modern. The quality of language of the manuscript is acceptable for me. So, I recommend that this manuscript may be accepted after minor revision. There are some advices for the authors: 1) In "1.1. Incidence-prevalence",the Incidence of gastric cancer in China may affect the conclusion of this part is not discussed, although this part was mentioned in the introduction.2)In "4.TREATMENT MODALITIES", targeted therapy of gastric cancer is not sufficiently discussed. For example, targeted therapy of claudin18.2 needs to be supplemented.



## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 89562

**Title:** Immunotherapy of gastric cancer: Present status and future perspectives

**Provenance and peer review:** Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05746825

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Associate Chief Physician, Associate Professor, Doctor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** Greece

**Manuscript submission date:** 2023-11-05

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2023-11-16 06:42

**Reviewer performed review:** 2023-11-19 23:58

**Review time:** 3 Days and 17 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Novelty of this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
<b>Creativity or innovation of this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation



<b>Scientific significance of the conclusion in this manuscript</b>	<input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

**SPECIFIC COMMENTS TO AUTHORS**

This is a very well written Editorial concerning the recently published paper of Li YN et al. entitled "Advances and key focus areas in gastric cancer immunotherapy: A comprehensive scientometric and clinical trial review (1999-2023)" in the World Journal of Gastroenterology. In present Editorial, the author discusses the conservative treatment (chemotherapy) of the various forms of gastric cancer. Special attention is given to modern therapeutic approaches with emphasis on immunotherapy which seems to be the future of GC treatment, especially in combination with chemotherapy. In this Editorial, the authors give their suggestions for immunotherapy of Gastric cancer.



**PEER-REVIEW REPORT**

**Name of journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 89562

**Title:** Immunotherapy of gastric cancer: Present status and future perspectives

**Provenance and peer review:** Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer’s code:** 07725470

**Position:** Peer Reviewer

**Academic degree:** Doctor, MD

**Professional title:** Attending Doctor, Professor

**Reviewer’s Country/Territory:** China

**Author’s Country/Territory:** Greece

**Manuscript submission date:** 2023-11-05

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2023-11-15 09:44

**Reviewer performed review:** 2023-11-29 09:20

**Review time:** 13 Days and 23 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Novelty of this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
<b>Creativity or innovation of this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation



<b>Scientific significance of the conclusion in this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

### SPECIFIC COMMENTS TO AUTHORS

This review paper provides a macro perspective on gastric cancer immunotherapy research over the past two decades through a comprehensive analysis of relevant literature. It summarizes the current status and future trends of gastric cancer immunotherapy, including advancements in immune checkpoint inhibitors, cell therapy, tumor vaccines, and non-specific immune modulators. This helps researchers and clinicians understand the development trajectory and future research directions in this field. The paper also outlooks the future directions of gastric cancer immunotherapy, such as research on novel biomarkers and combination therapies with other modalities. These insights are inspirational for advancing gastric cancer treatment research. The author(s) have rich professional background and research experience, which adds to the credibility and authority of the paper. The paper adopts scientific methodologies, such as systematic literature review and clinical trial analysis, to effectively support the authors' viewpoints and conclusions. Overall, the paper structure is clear, the theme salient, but there remains room for improvement in some details and depth. The manuscript is worth publication if the following major revisions can be done properly:



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** office@baishideng.com  
**https://**www.wjgnet.com

Below are my comments: 1. Given the title “Immunotherapy of Gastric cancer: Present status and future perspectives.”, readers would expect the content to mainly cover the current status and potential future developments of gastric cancer immunotherapy. However, the provided paragraphs touch on various aspects beyond immunotherapy, including epidemiology, pathophysiology, and other treatment strategies of gastric cancer. While these contents are important for readers to comprehensively understand gastric cancer, they can be confusing and divert attention from the main focus on immunotherapy. In addition, there does not seem to be sufficient coverage on the details of the present situation and future of immunotherapy, which may disappoint readers. Hence, I agree the structure of the paper needs refinement to make it more coherent and targeted. It would be helpful to first briefly introduce the epidemiology and pathophysiology of gastric cancer, then thoroughly discuss the status quo of gastric cancer immunotherapy, including current treatment methods, efficacy, and existing issues, before exploring likely developmental trends and research directions moving forward. Other treatment strategies can be mentioned as references where appropriate but should not dominate. 2. While the paper provides an in-depth introduction of the different types and methods of immunotherapy for gastric cancer, including immune checkpoint inhibitors and cell-based therapies, the analysis of the specific efficacy, advantages and limitations of these therapies is insufficient. More in-depth discussion is needed on the mechanisms of immunotherapy and practical applications of biomarkers, especially regarding immune checkpoint inhibitors and interactions with the unique tumor microenvironment in gastric cancer. 3. The paper does not thoroughly review some of the most recent immunotherapy strategies such as non-specific immune modulators and tumor vaccines. Enriching the discussion with these emerging areas will broaden and deepen the scope of the paper, thus providing a more comprehensive overview of the current state of cancer immunotherapy. I would suggest the author



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** office@baishideng.com  
**https://**www.wjgnet.com

expand the literature review to include recent advancements in various aspects of immunotherapy: for example, novel tumor vaccine methods such as oncolytic virus vaccines, and cutting-edge areas like neoantigen-based personalized vaccines. 4. Regarding the use of technical terminology, I recommend the author provide brief explanations or definitions when specialized terms first appear, to aid comprehension for non-expert readers. For example, “cytokine-induced killer (CIK) cells”, “chimeric antigen receptor T cell (CAR-T cell) therapy”, and other concepts should be explained on their maiden appearance - clarifying what they are and their roles and significance in gastric cancer immunotherapy. 5. For consistency, the format of the cited references should be uniform throughout. Additionally, please verify that all referenced sources are accurate and contain no errors. I noticed some references are missing the digital object identifier (DOI) or PubMed ID (PMID).